Siris Bio-Sciences

Siris Biosciences was a biotechnology startup based in Cambridge, Massachusetts, focused on developing a proprietary platform for the targeted delivery of therapeutic payloads to the tumor microenvironment. The company's core technology utilized supramolecular nanoparticles (SNPs) designed to deliver combinations of immunomodulators, such as STING agonists and checkpoint inhibitors, directly to myeloid cells and tumor tissues. By modulating the immune landscape of the tumor, Siris aimed to repolarize pro-tumor M2 macrophages into anti-tumor M1 macrophages to improve outcomes for patients with solid tumors. The company was founded based on research from the Brigham and Women's Hospital and Harvard Medical School, though it appears to have ceased active operations around 2019.